Dendritic cell immunotherapy: Mapping the way

Nature Medicine

Volumn 10, Issue 5, 2004, Pages 475-480

  Figdor, Carl G ^a   De Vries, I Jolanda M ^a   Lesterhuis, W Joost ^a   Melief, Cornelis J M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD209 ANTIGEN; CD34 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; MATRIX METALLOPROTEINASE; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VACCINATION;

ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS;

EID: 2442647551     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1039     Document Type: Review

References (48)

1. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58 (1996).
2. Banchereau, J., Schuler-Thurner, B., Palucka, A.K. & Schuler, G. Dendritic cells as vectors for therapy. Cell 106, 271-274 (2001).
3. Steinman, R.M. & Pope, M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109, 1519-1526 (2002).
4. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
5. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118 (1994).
6. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55, 1099-1104 (1995).
7. + hematopoietic progenitor cells. Int. J. Cancer 86, 385-392 (2000).
8. + progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
9. Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417 (2002).
10. De Vries, I.J. et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63, 12-17 (2003).
11. Martin-Fontecha, A. et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198, 615-621 (2003).
12. Ratzinger, G. et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J. Immunol. 168, 4361-4371 (2002).
13. Garg, S. et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat. Immunol. 4, 907-912 (2003).
14. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4, 579-585 (2003).
15. Miller, M.J., Hejazi, A.S., Wei, S.H., Cahalan, M.D. & Parker, I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc. Natl. Acad. Sci. USA 101, 998-1003 (2004).
16. Jonuleit, H. et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93, 243-251 (2001).
17. Mullins, D.W. et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198, 1023-1034 (2003).
18. Pulendran, B. et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566-572 (2000).
19. Maraskovsky, E. et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96, 878-884 (2000).
20. MacDonald, K.P. et al, Characterization of human blood dendritic cell subsets. Blood 100, 4512-4520 (2002).
21. Boonstra, A. et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197, 101-109 (2003).
22. Salio, M. et al. Plasmacytoid dendritic cells prime IFN-γ -secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33, 1052-1062 (2003).
23. Krug, A. et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026-3037 (2001).
24. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358 (2002).
25. Toes, R.E., Ossendorp, F., Offringa, R. & Melief, C.J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756 (1999).
26. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279 (2003).
27. Melief, C.J., Van Der Burg, S.H., Toes, R.E., Ossendorp, F. & Offringa, R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188, 177-182 (2002).
28. Schuler-Thurner, B. et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288 (2002).
29. Fearon, E.R. et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403 (1990).
30. + T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
31. Engering, A., Geijtenbeek, T.B. & van Kooyk, Y. Immune escape through C-type lectins on dendritic cells. Trends Immunol. 23, 480-485 (2002).
32. Rea, D. et al. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 95, 3162-3167 (2000).
33. Adorini, L., Penna, G., Giarratana, N. & Uskokovic, M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem. 88, 227-233 (2003).
34. Martin, E., O'Sullivan, B., Low, P. & Thomas, R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18, 155-167 (2003).
35. Gilboa, E., Nair, S.K. & Lyerly, H.K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46, 82-87 (1998).
36. Nestle, F.O., Banchereau, J. & Hart, D. Dendritic cells: On the move from bench to bedside. Nat. Med. 7, 761-765 (2001).
37. de Vries, I.J. et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9, 5091-5100 (2003).
38. Dhodapkar, M.V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173-180 (1999).
39. + T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105, R9-R14 (2000).
40. Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
41. Mackensen, A., Drager, R., Schlesier, M., Mertelsmann, R. & Lindemann, A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol. Immunother. 49, 152-156 (2000).
42. Jonuleit, H. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
43. Bostanci, A. & Vogel, G. Research misconduct. German inquiry finds flaws, not fraud. Science 298, 1531-1533 (2002).
44. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
45. Geiger, J.D. et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61, 8513-8519 (2001).
46. Cerundolo, V., Hermans, I.F. & Salio, M. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5, 7-10 (2004).
47. Wakkach, A. et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617 (2003).
48. Phan, G.Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100, 8372-8377 (2003).